On Monday, Pliant Therapeutics Inc (NASDAQ: PLRX) opened higher 5.97% from the last session, before settling in for the closing price of $1.34. Price fluctuations for PLRX have ranged from $1.10 to $16.52 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -52.88% over the last five years. Company’s average yearly earnings per share was noted 23.99% at the time writing. With a float of $53.12 million, this company’s outstanding shares have now reached $60.86 million.
The firm has a total of 171 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Pliant Therapeutics Inc (PLRX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Pliant Therapeutics Inc is 13.46%, while institutional ownership is 99.89%. The most recent insider transaction that took place on Jan 17 ’25, was worth 587,150. In this transaction President and CEO of this company sold 52,419 shares at a rate of $11.20, taking the stock ownership to the 430,517 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Financial Officer sold 20,148 for $11.20, making the entire transaction worth $225,680. This insider now owns 262,608 shares in total.
Pliant Therapeutics Inc (PLRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.00% during the next five years compared to -78.30% drop over the previous five years of trading.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Check out the current performance indicators for Pliant Therapeutics Inc (PLRX). In the past quarter, the stock posted a quick ratio of 10.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.47, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -2.43 in one year’s time.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
Analysing the last 5-days average volume posted by the [Pliant Therapeutics Inc, PLRX], we can find that recorded value of 1.12 million was lower than the volume posted last year of 2.47 million. As of the previous 9 days, the stock’s Stochastic %D was 66.19%. Additionally, its Average True Range was 0.21.
During the past 100 days, Pliant Therapeutics Inc’s (PLRX) raw stochastic average was set at 2.18%, which indicates a significant decrease from 69.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.25% in the past 14 days, which was lower than the 229.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.8598, while its 200-day Moving Average is $10.3669. Now, the first resistance to watch is $1.4700. This is followed by the second major resistance level at $1.5200. The third major resistance level sits at $1.6000. If the price goes on to break the first support level at $1.3400, it is likely to go to the next support level at $1.2600. Now, if the price goes above the second support level, the third support stands at $1.2100.
Pliant Therapeutics Inc (NASDAQ: PLRX) Key Stats
There are currently 61,236K shares outstanding in the company with a market cap of 87.17 million. Presently, the company’s annual sales total 0 K according to its annual income of -210,300 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -49,730 K.
